Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States

References

• Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl1):74-81
   Web of Science ®Google Scholar
• Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67
   PubMed Web of Science ®Google Scholar
• US Centers for Disease Control (CDC). Hepatitis C FAQs for health professionals, 2016. http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Accessed January 10, 2016
   Google Scholar
• US Centers for Disease Control (CDC). Viral hepatitis surveillance, United States, 2013. http://www.cdc.gov/hepatitis/statistics/2013surveillance/pdfs/2013hepsurveillancerpt.pdf. Accessed January 19, 2016
   Google Scholar
• Williams IT, Bell BP, Kuhnert W, et al. Incidence and transmission patterns of acute hepatitis C in the United States, 1982–2006. Arch Intern Med 2011;171:242-8
   PubMed Web of Science ®Google Scholar
• European Association of the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 2012;32(Suppl1):2-8
   Web of Science ®Google Scholar
• Guedj J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA 2013;110:3991-6
   PubMed Web of Science ®Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61:1127-35
   PubMed Web of Science ®Google Scholar
• McEwan P, Kim R, Yuan Y. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl Health Econ Health Policy 2013;11:53-63
   PubMedGoogle Scholar
• McEwan P, Ward T, Webster S, et al. Estimating the long-term clinical and economic outcomes of daclatasvir plus asunaprevir in difficult-to-treat Japanese patients chronically infected with hepatitis C genotype 1b. Value Health Region Iss 2014;3:136-45
   PubMedGoogle Scholar
• McEwan P, Ward T, Yuan Y, et al. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 2013;58:54-64
   PubMed Web of Science ®Google Scholar
• McEwan P, Ward T, Chen C-J, et al. Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection. Value Health Region Iss 2014;3:5-11
   PubMedGoogle Scholar
• McEwan P, Ward T, Bennett H, et al. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS One 2015 Jan 30;10:e0117334
   PubMed Web of Science ®Google Scholar
• Annemans L, Warie H, Nechelput M, et al. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients. Acta Gastro-enterol Belg 2004;67:1-8
   PubMed Web of Science ®Google Scholar
• Buti M, Casado MA, Fosbrook L, et al. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol 2000;33:651-8
   PubMed Web of Science ®Google Scholar
• Hornberger J, Farci P, Prati D, et al. The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase. J Viral Hepat 2006;13:377-86
   PubMed Web of Science ®Google Scholar
• Ishida H, Inoue Y, Wong JB, et al. Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial. Hepatol Res 2004;28:125-36
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425-32
   PubMed Web of Science ®Google Scholar
• National Institue for Health and Care Excellence. Technology appraisal TA252: Telaprevir for the treatment of genotype 1 chronic hepatitis C; 2012 [updated November 2013]. http://guidance.nice.org.uk/TA252. Accessed January 2014
   Google Scholar
• McGarry LJ, Pawar VS, Panchmatia HR, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012;55:1344-55
   PubMed Web of Science ®Google Scholar
• US Centers for Disease Control (CDC). Viral hepatitis statistics and surveillance: Table 4.4 reported cases of laboratory-confirmed, hepatitis C (past or present) infection, by sex, race/ethnicity, age group, and positive lab tests; 2011. http://www.cdc.gov/hepatitis/Statistics/2011Surveillance/Table4.4.htm. Accessed January 26, 2016
   Google Scholar
• Martin NK, Vickerman P, Miners A, et al. Cost‐effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 2012;55:49-57
   PubMed Web of Science ®Google Scholar
• Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418-31
   PubMed Web of Science ®Google Scholar
• Townsend R, McEwan P, Kim R, et al. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health J Int Soc Pharmacoeconom Outcomes Res 2011;14:1068-77
   PubMed Web of Science ®Google Scholar
• Coffin PO, Scott JD, Golden MR, et al. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis Offic Publ Infect Dis Soc Am 2012;54:1259-71
   PubMed Web of Science ®Google Scholar
• Ferrante SA, Chhatwal J, Brass CA, et al. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis 2013;13:190
   PubMed Web of Science ®Google Scholar
• Javanbakht M, Mirahmadizadeh A, Mashayekhi A. The long-term effectiveness of methadone maintenance treatment in prevention of hepatitis C virus among illicit drug users: a modeling study. Iran Red Crescent Med J 2014;16:e13484
   PubMed Web of Science ®Google Scholar
• The United States of America, Life tables (period 1x1), per gender [updated 16 Nov 2012]. http://www.mortality.org/hmd/USA/STATS/fltper_1x1.txt. Accessed August 2015
   Google Scholar
• Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001
   PubMed Web of Science ®Google Scholar
• Swallow E, Song J, Yuan Y, et al. Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison. J Comparative Effectiveness Res 2016;5:129-39
   PubMed Web of Science ®Google Scholar
• Health Analytics database, Market shares utilization data for Copegus, Rebetol, RibaPak, Ribasphere and Ribavirin in the United States, 2014
   Google Scholar
• Buikema AR, Rosenblatt LC, Liu F, et al. Burden of side effects associated with treatment of hepatitis C. Poster # 964. American Association for the Study of Liver Diseases (AASLD), 65th Annual Meeting; November 7–11, 2014
   Google Scholar
• American Association for the Study of Liver Disease (AASLD). Recommendations for testing, managing, and treating hepatitis C; Revised date: August 11, 2014. http://www.hcvguidelines.org. Accessed October 2014
   Google Scholar
• Davis KL, Mitra D, Medjedovic J, et al. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011;45:e17-24
   PubMed Web of Science ®Google Scholar
• McAdam-Marx C, McGarry LJ, Hane CA, et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011;17:531-46
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. All urban consumers (current series), Health CPI, Series ID: CUSR0000SAM, Area: U.S. city average, Item: Medical care; 2004–2014. Washington, DC: Bureau of Labor Statistics. http://stats.bls.gov/home.htm. Accessed October 2, 2014
   Google Scholar
• Younossi ZM, Stepanova M, Cure S, et al. Estimating health status using EQ-5D for CHRONIC HEPatitis C (CH-C) patients treated with sofosbuvir containing regimens. 49th Annual Meeting of the European Association for the Study of the Liver (EASL); April 9–13, 2014
   Google Scholar
• Time Preference. By Lipscomb J, Weinstein MC, Torrance GW. In Cost-effectiveness in Health and Medicine. By Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). New York: Oxford University Press, 1996
   Google Scholar
• McEwan P, Ward T, Chen C-J, et al. Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection. Value Health Region 2014;3C:5-11
   Google Scholar
• Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407-19
   PubMed Web of Science ®Google Scholar
• McEwan P, Webster S, Ward T, et al. Estimating the cost-effectiveness of daclatasvir regimens for patients with advanced chronic hepatitis C in the UK. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 20th Annual Meeting; May 16–20, 2015
   Google Scholar
• McEwan P, Ward T, Webster S, et al. Estimating the cost-effectiveness of 12 weeks of daclatasvir + sofosbuvir in patients chronically infected with HCV genotype 3. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 20th Annual Meeting; May 16–20, 2015
   Google Scholar
• Moshyk A, Martel MJ, Tahami Monfared AA, et al. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada. J Med Econ. 2016;19:181-92
   PubMed Web of Science ®Google Scholar
• Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608-17
   PubMed Web of Science ®Google Scholar
• American Association for the Study of Liver Disease (AASLD). Recommendations for testing, managing, and treating hepatitis C; Updated July 6, 2016. www.hcvguidelines.org. Accessed March 2017
   Google Scholar
• Truven Health Analytics Inc. RED BOOK Online?, http://sites.truvenhealth.com/redbook/index.html. Accessed July 2014
   Google Scholar
• Centers for Medicare and Medicaid Services (CMS), Clinical Laboratory Fee Schedule, National Limit Payment. https://www.cms.gov/medicare/medicare-fee-for-service-payment/clinicallabfeesched/clinlab.html. Accessed January 2016
   Google Scholar
• Centers for Medicare and Medicaid Services (CMS), Physician Fee Schedule, National payment amount by CPT code. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-Federal-Regulation-Notices-Items/CMS-1600-FC.html. Accessed January 2016
   Google Scholar
• Centers for Medicare and Medicaid Services (CMS), Hospital Outpatient PPS File, Payment rate by HCPCS code, 2014
   Google Scholar